> Dear Seafood list members,
>
> I am distributing this for Dr. Bill Harris, who spoke at IIFET 2000 on the
> effects of seafood consumption
> on human health. This workshop near Washington DC, may be of interest to those
> of you interested in the details of Omega-3 fatty acids' effect on particular
> human health problems.
> Regards, Ann Shriver, IIFET
>
>
> INTERNATIONAL WORKSHOP ON OMEGA-3 FATTY ACIDS, DIABETES AND CARDIOVASCULAR
> RISK
> BETHESDA, MD
> NOV 30-DEC 2, 2000
>
> This workshop is designed to explore the question of whether of long chain,
> marine n-3 fatty acids (up to 3 g/d) may reduce risk for CVD in patients
> with type 2 diabetes. It is an information-intensive program that emphasizes
> discussion and interaction among the experts in attendance. The three
> primary questions upon which this workshop will focus are:
>
> · are n-3 fatty acids efficacious in lowering CVD risk in type 2 diabetes?
> · are n-3 fatty acids safe in type 2 diabetes?
> · should a major clinical trial be mounted, or is additional research needed
> before undertaking such a trial; if so, what are the questions that must be
> answered?
>
> Information regarding registration is given after the program and can be
> found at our website: http://www.omega3ri.org.
>
> WORKSHOP SCHEDULE
>
> Thursday, November 30, 2000
> Introductory Session
> Chairs: William Harris, PhD and Robert Katz, PhD
> 19:00 Reception
>
> 20:00 How Do We Die - Markers or Mediators?
> William Lands, PhD
> 20:30 Diabetes in Native Americans: Dietary approaches to reducing CVD
> Risk
> Sven Ebbesson, PhD
> 21:00 The GISSI Prevenzione Study: Principal Findings
> Roberto Marchioli, MD
>
> Friday, December 1, 2000
> 08:00 Welcome
> William Harris, PhD
>
> Session 1. Omega-3 FAs and CV Events in Diabetic Patients: Clinical Trial
> and Epidemiologic Evidence
> Chairs: Roberto Marchioli, MD and David Siscovick, MD
> 08:10 Effects of n-3 FAs in diabetic patients in the GISSI Prevention
> Study:
> Roberto Marchioli, MD
> 08:30 Epidemiologic evidence for a protective effect of fish in diabetic
> patients
> Martha Daviglus, MD, PhD
> 08:50 Prevention of sudden death by low intakes of n-3 FAs
> David Siscovick, MD
> 09:10 Discussion and Questions
> Session Chairs
>
> Session 2. Diabetes and CV Disease: Magnification of Risk
> Chairs: Steve Haffner, MD and James O'Keefe, MD
>
> 09:30 Diabetes as a Risk Factor for CHD
> Steve Haffner, MD
> 09:50 Diabetes, lipoproteins, and atherosclerosis
> Henry Ginsberg, MD
> 10:10 Break
> 10:30 Hemostatic abnormalities in type 2 diabetes
> Norberta Schoene, PhD
> 10:50 Alterations in blood pressure and endothelial function in type 2
> diabetes
> James Sowers, MD
> 11:10 Diabetes and Autonomic Dysfunction: A cause for increased CHD risk?
> James O'Keefe, MD
> 11:30 Discussion and questions
> Session Chairs
> 11:45 Break for Lunch (catered for Invited Speakers)
>
> Working Lunch for speakers in sessions 1 and 2
>
> Session 3. Effects of n-3 FAs on Insulin and Glucose Metabolism: Basic
> Science
> Chairs: Len Storlien, PhD and John Miles, MD
>
> 12:40 Fundamentals of Carbohydrate and Lipid Metabolism in Diabetes
> John Miles, MD
> 13:00 Insulin resistance and n-3 FAs: Animal and cell culture
> Tom Clandinin, PhD
> 13:20 Insulin resistance and n-3 FAs: Human
> Len Storlien, PhD
> 13:40 n-3 FAs and expression of genes controlling carbohydrate metabolism
> James Ntambi, PhD
> 14:00 PPAR, SREBP and n-3 FAs
> Donald Jump, PhD
> 14:20 Discussion and Break
>
> Session 4. Effects of n-3 FAs on Insulin and Glucose Metabolism: Safety
> Issues
> Chairs: Henry Ginsberg, MD and Bill Connor, MD
>
> 15:00 Historical concerns regarding the use of n-3 FAs in diabetic patients
> Bengt Vessby, MD
> 15:20 Multicenter trial of n-3 fatty acids in type 2 diabetic patients
>
> Angella Rivellese, MD
> 15:40 Diabetic control is not adversely affected by n-3 FA supplementation
> William Connor, MD
> 16:00 Glycemic control and marine n-3 FAs: A meta-analysis
> Mark Deeg, MD,
> 16:20 Discussion and Questions
> Session Chairs
>
> Effects of n-3 FAs on risk factors for CV disease
>
> Session 5: Vascular Biology and Blood Pressure
> Chairs: Christie Ballantyne, MD and Clemens von Schacky, MD
>
> 16:40 Circulating adhesion molecules and n-3 FAs
> Christie Ballantyne, MD
> 17:00 Effects of n-3 FAs on blood pressure
> Trevor Mori, PhD
> 17:20 Fish oils and blood pressure in diabetic patients
> Ingrid Toft, MD, PhD
> 17:40 Discussion and Questions
>
> 18:00 Dismiss
>
> 19:00 - Conference Dinner and Special Program
>
> Saturday, December 2, 2000
>
> 7:00 Working Breakfast for Speakers in Sessions 3 and 4
>
> Session 5 (continued): Vascular Biology and Blood Pressure
> 8:00 Modulation of endothelial health by n-3 FAs
> Gary McVeigh, MD
> 8:20 Diminishing inflammatory responses with n-3 FAs
> Clemens von Schacky, MD
> 8:40 Discussion and Questions
> Session Chairs
>
> Session 6: Lipoprotein Metabolism and Platelet Function
> Chairs: Ernie Schaefer, MD and Howard Knapp, MD, PhD
>
> 8:50 High fish diets and remnant lipoprotein
> Ernie Schaefer, MD
> 9:10 Effects of n-3 fatty acids on LDL-Cholesterol
> William S. Harris, PhD
> 9:30 Omega-3 fatty acids in the treatment of the atherogenic lipoprotein
> phenotype
> Christine Williams, PhD
> 9:50 Break
> 10:10 Omega-3 fatty acids and statins: combined therapy for dyslipidemia
> Arne Nordoy, MD
> 10:30 Overview of n-3 FAs, hemostasis and diabetes
> Howard Knapp, MD, PhD
> 10:50 Discussion and Questions
> Session Chairs
>
> Session 7. Effects of n-3 FAs on Excitable Membranes: Implications for
> Diabetes
> Chair: Alex Leaf, MD
>
> 11:10 Can n-3 FAs improve heart rate variability?
> Eric Berg Schmidt, MD
> 11:30 Omega-3 fatty acids and Arrhythmias: Animal Studies
> Peter McLennan, PhD
> 11:50 Altering metabolic function of excitable tissues with n-3 FAs
> Alex Leaf, MD
> 12:10 Discussion and Questions
>
> 12:30 Break - Catered Lunch for Invited Speakers
>
> Working lunch for Speakers in Sessions 5 - 8
>
> Session 8: Nutritional Issues
> Chair: Artemis Simopoulos, MD
> 13:20 Historical perspective on n-3 FA consumption
> Artemis Simopoulos, MD
> 13:40 Incorporating n-3 FAs into diabetic diets
> Sonja Connor, MS, RD
>
> Summary, Conclusions and Recommendations
>
> Chairs: William Harris, John Miles, James O'Keefe, Artemis Simopoulos,
> Robert Katz
>
> 14:00 Group Discussion of the following questions (addressed in
> working
> lunches)
>
> 1. Does it appear likely that up to 3 g of n-3 FAs will materially reduce
> CVD risk in diabetes?
> 2. Are there significant safety concerns regarding the use of up to 3 g of
> n-3 FAs/day in patients with type 2 diabetes?
> 3. Is it time for a major clinical trial to test the hypothesis that n-3
> fatty acids can reduce CV events in patients with type 2 diabetes? If yes,
> how should it be designed? If no, why not?
>
> 15:30 Closing remarks
>
> William S. Harris, PhD
> Lipid and Diabetes Research Center
> Saint Luke's Hospital
> 4320 Wornall Road, Suite 128
> Kansas City, MO 64111
> phone-816/932/8235
> fax-816/932-8278
> wharris@saint-lukes.org
>
>
This archive was generated by hypermail 2b29 : Mon Nov 06 2000 - 11:38:01 PST